Premium
Hepatocyte transplantation in rats with decompensated cirrhosis
Author(s) -
Kobayashi Naoya,
Ito Masahiro,
Nakamura Junta,
Cai Jin,
Gao Chen,
Hammel James M.,
Fox Ira J.
Publication year - 2000
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1053/he.2000.5636
Subject(s) - transplantation , cirrhosis , medicine , hepatocyte , carbon tetrachloride , hepatic encephalopathy , liver transplantation , albumin , bilirubin , gastroenterology , chemistry , in vitro , biochemistry , organic chemistry
Hepatocyte transplantation improves the survival of laboratory animals with experimentally induced acute liver failure and the physiological abnormalities associated with liver‐based metabolic deficiencies. The role of hepatocyte transplantation in treating decompensated liver cirrhosis, however, has not been studied in depth. To address this issue, cirrhosis was induced using phenobarbital and carbon tetrachloride (CCL 4 ) and animals were studied only when evidence of liver failure did not improve when CCL 4 was held for 4 weeks. Animals received intrasplenic transplantation of syngeneic rat hepatocytes (G1); intraperitoneal transplantation of syngeneic rat hepatocytes (G2); intraperitoneal transplantation of a cellular homogenate of syngeneic rat hepatocytes (G3); intraperitoneal transplantation of syngeneic rat bone marrow cells (G4); or intrasplenic injection of Dulbecco's modified Eagle medium (DMEM) (G5). After transplantation, body weight and serum albumin levels deteriorated over time in all control (G2‐G5) animals but did not deteriorate in animals receiving intrasplenic hepatocyte transplantation (G1) ( P < .01). Prothrombin time (PT), total bilirubin, serum ammonia, and hepatic encephalopathy score were also significantly improved toward normal in animals receiving intrasplenic hepatocyte transplantation ( P < .01). More importantly, survival was prolonged after a single infusion of hepatocytes and a second infusion prolonged survival from 15 to 128 days ( P < .01). Thus, hepatocyte transplantation can improve liver function and prolong the survival of rats with irreversible, decompensated cirrhosis and may be useful in the treatment of cirrhosis in humans.